These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37516343)

  • 21. Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors.
    Jiménez-Alberto A; Ribas-Aparicio RM; Aparicio-Ozores G; Castelán-Vega JA
    Comput Biol Chem; 2020 Oct; 88():107325. PubMed ID: 32623357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds.
    Liu P; Liu H; Sun Q; Liang H; Li C; Deng X; Liu Y; Lai L
    Eur J Med Chem; 2020 Nov; 206():112702. PubMed ID: 32798789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19.
    Anirudhan V; Lee H; Cheng H; Cooper L; Rong L
    J Med Virol; 2021 May; 93(5):2722-2734. PubMed ID: 33475167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential SARS-CoV-2 protease M
    Kouznetsova VL; Huang DZ; Tsigelny IF
    Phys Biol; 2021 Feb; 18(2):025001. PubMed ID: 33203811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.
    Kandeel M; Al-Nazawi M
    Life Sci; 2020 Jun; 251():117627. PubMed ID: 32251634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ligand-based discovery of coronavirus main protease inhibitors using MACAW molecular embeddings.
    Dong J; Varbanov M; Philippot S; Vreken F; Zeng WB; Blay V
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):24-35. PubMed ID: 36305272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study.
    Wang J
    J Chem Inf Model; 2020 Jun; 60(6):3277-3286. PubMed ID: 32315171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-HIV and anti-HCV small molecule protease inhibitors in-silico repurposing against SARS-CoV-2 M
    Sultan A; Ali R; Ishrat R; Ali S
    J Biomol Struct Dyn; 2022; 40(23):12848-12862. PubMed ID: 34569411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of novel inhibitors of SARS-CoV-2 main protease.
    Zheng L; Chen Y; Bao J; He L; Dong S; Qi Y; Zhang JZH
    J Biomol Struct Dyn; 2022; 40(23):12526-12534. PubMed ID: 34472424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
    Mandour YM; Zlotos DP; Alaraby Salem M
    J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022.
    Pang X; Xu W; Liu Y; Li H; Chen L
    Eur J Med Chem; 2023 Sep; 257():115491. PubMed ID: 37244162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
    Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
    PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
    Goyal B; Goyal D
    ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
    Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA
    Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors.
    He J; Hu L; Huang X; Wang C; Zhang Z; Wang Y; Zhang D; Ye W
    Int J Antimicrob Agents; 2020 Aug; 56(2):106055. PubMed ID: 32534187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
    Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protein degradation: a novel computational approach to design protein degrader probes for main protease of SARS-CoV-2.
    Shaheer M; Singh R; Sobhia ME
    J Biomol Struct Dyn; 2022; 40(21):10905-10917. PubMed ID: 34328382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
    Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
    Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elucidation of Binding Features and Dissociation Pathways of Inhibitors and Modulators in SARS-CoV-2 Main Protease by Multiple Molecular Dynamics Simulations.
    Xu L; Xie L; Zhang D; Xu X
    Molecules; 2022 Oct; 27(20):. PubMed ID: 36296416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.